Narcolepsy is a chronic neurological disorder caused by progressive hypocretin/orexin neuron loss, manifesting as excessive daytime sleepiness, cataplexy, sleep paralysis, and fragmented nocturnal sleep. It remains substantially underdiagnosed with highly variable access to specialized pharmacotherapy.

Gamma-hydroxybutyrate (GHB) class agents consolidate nocturnal sleep via GABA-B receptor agonism, reducing excessive daytime sleepiness and cataplexy. Low-sodium GHB formulations achieve equivalent efficacy while reducing per-dose sodium load by ~92%, advantageous for patients with cardiovascular or sodium-sensitive comorbidities. Real-world prescribing analyses reveal a nearly 50% increase in high-cost narcolepsy drug utilization over recent years, with GHB-class agents representing a dominant proportion of defined daily doses, yet marked geographic and institutional access disparities persist. Optimal candidacy assessment, careful titration, CNS depression and drug interaction risk mitigation, and equitable access strategies remain key clinical priorities. Sleep medicine specialists, neurologists, and psychiatrists will benefit from peer discussion of GHB-class therapy evidence, real-world access challenges, and practical management.

How do you approach initiation and titration of gamma-hydroxybutyrate class therapy in narcolepsy patients, and what patient-specific factors most influence your pharmacotherapy selection? What strategies have you found effective in overcoming access barriers, including formulary restrictions and geographic disparities, for patients who would benefit from GHB-class treatment?

Narcolepsy is a chronic neurological disorder caused by progressive loss of hypothalamic hypocretin/orexin neurons, producing excessive daytime sleepiness (EDS), cataplexy, fragmented nocturnal sleep, sleep paralysis, and hypnagogic hallucinations. Despite profound impacts on quality of life and occupational functioning, narcolepsy remains substantially underdiagnosed and undertreated, with access to specialized pharmacotherapy highly variable across healthcare systems.

Effective pharmacological management targets multiple symptom domains through mechanistically distinct drug classes — including agents that promote wakefulness via dopaminergic and noradrenergic pathways, anticataplectic therapies acting on norepinephrine reuptake or REM sleep regulation, and agents that consolidate nocturnal sleep architecture through inhibitory neurotransmitter modulation. Cardiovascular comorbidities are prevalent in the narcolepsy population, and ionic composition of available agents — including per-dose sodium load — represents a clinically meaningful variable in pharmacotherapy selection for patients with hypertension or sodium-sensitive conditions. Real-world prescribing analyses reveal a nearly 50% increase in high-cost narcolepsy drug utilization in recent years, yet marked geographic and institutional access disparities persist. Careful patient selection, structured titration protocols, CNS depression risk mitigation, and proactive prior authorization navigation are central to optimizing clinical outcomes in practice.

How do cardiovascular comorbidities — particularly hypertension and sodium sensitivity — factor into your pharmacotherapy selection for narcolepsy patients, and what monitoring approach do you apply during titration?

What strategies have you found effective in overcoming formulary and prior authorization barriers for patients who would benefit from specialized narcolepsy pharmacotherapy, and how do you support adherence through the titration phase?